UBS Group’s Crinetics Pharmaceuticals CRNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21M | Sell |
561,165
-10,734
| -2% | -$399K | ﹤0.01% | 2629 |
|
|
2026
Q1 | $20.8M | Sell |
571,899
-336,293
| -37% | -$15M | ﹤0.01% | 2537 |
|
|
2025
Q4 | $42.3M | Buy |
908,192
+500,470
| +123% | +$22.3M | 0.01% | 1789 |
|
|
2025
Q3 | $17M | Buy |
407,722
+87,177
| +27% | +$2.79M | ﹤0.01% | 2743 |
|
|
2025
Q2 | $9.22M | Buy |
320,545
+4,886
| +2% | +$151K | ﹤0.01% | 3161 |
|
|
2025
Q1 | $10.6M | Sell |
315,659
-392,071
| -55% | -$14.6M | ﹤0.01% | 2976 |
|
|
2024
Q4 | $36.2M | Buy |
707,730
+524,844
| +287% | +$29.4M | 0.01% | 1760 |
|
|
2024
Q3 | $9.35M | Sell |
182,886
-56
| -0% | -$2.89K | ﹤0.01% | 2433 |
|
|
2024
Q2 | $8.19M | Sell |
182,942
-64,861
| -26% | -$3M | ﹤0.01% | 2401 |
|
|
2024
Q1 | $11.6M | Buy |
247,803
+109,338
| +79% | +$4.28M | ﹤0.01% | 2149 |
|
|
2023
Q4 | $4.93M | Buy |
138,465
+56,607
| +69% | +$1.74M | ﹤0.01% | 2794 |
|
|
2023
Q3 | $2.43M | Sell |
81,858
-63,835
| -44% | -$1.32M | ﹤0.01% | 3256 |
|
|
2023
Q2 | $2.63M | Buy |
145,693
+86,525
| +146% | +$1.73M | ﹤0.01% | 3260 |
|
|
2023
Q1 | $950K | Sell |
59,168
-21,526
| -27% | -$398K | ﹤0.01% | 4152 |
|
|
2022
Q4 | $1.48M | Buy |
80,694
+72,555
| +891% | +$1.28M | ﹤0.01% | 3691 |
|
|
2022
Q3 | $160K | Sell |
8,139
-11,041
| -58% | -$225K | ﹤0.01% | 5285 |
|
|
2022
Q2 | $358K | Sell |
19,180
-49,313
| -72% | -$984K | ﹤0.01% | 4512 |
|
|
2022
Q1 | $1.5M | Buy |
68,493
+15,673
| +30% | +$317K | ﹤0.01% | 3711 |
|
|
2021
Q4 | $1.5M | Buy |
52,820
+31,593
| +149% | +$779K | ﹤0.01% | 4014 |
|
|
2021
Q3 | $447K | Buy |
+21,227
| New | +$444K | ﹤0.01% | 4809 |
|
|
2021
Q2 | – | Sell |
-4,129
| Closed | -$63K | – | 9429 |
|
|
2021
Q1 | $63K | Buy |
4,129
+2,030
| +97% | +$31.5K | ﹤0.01% | 6324 |
|
|
2020
Q4 | $30K | Buy |
+2,099
| New | +$29.2K | ﹤0.01% | 6629 |
|
|
2020
Q3 | – | Sell |
-9,093
| Closed | -$159K | – | 8040 |
|
|
2020
Q2 | $159K | Buy |
9,093
+877
| +11% | +$15K | ﹤0.01% | 4963 |
|
|
2020
Q1 | $121K | Sell |
8,216
-8,871
| -52% | -$182K | ﹤0.01% | 5114 |
|
|
2019
Q4 | $429K | Buy |
17,087
+7,888
| +86% | +$150K | ﹤0.01% | 4972 |
|
|
2019
Q3 | $138K | Buy |
9,199
+8,514
| +1,243% | +$166K | ﹤0.01% | 5545 |
|
|
2019
Q2 | $17K | Sell |
685
-42,731
| -98% | -$1.06M | ﹤0.01% | 6725 |
|
|
2019
Q1 | $988K | Buy |
43,416
+42,821
| +7,197% | +$1.05M | ﹤0.01% | 3602 |
|
|
2018
Q4 | $18K | Sell |
595
-1,042
| -64% | -$29.3K | ﹤0.01% | 6866 |
|
|
2018
Q3 | $47K | Buy |
+1,637
| New | +$48.6K | ﹤0.01% | 6200 |
|
Other funds holding CRNX
FCM
DCM
JT
UBS Group's CRNX Position: Q2 2026 in Review
UBS Group reduced its Crinetics Pharmaceuticals (CRNX) stake by 1.9% in Q2 2026, selling an estimated $399K and leaving 561,165 shares worth $21M. The position accounts for ﹤0.01% of the portfolio, ranked #2629.
UBS Group first reported a position in CRNX in Q3 2018 and has held it in 30 quarters since. The position peaked at $42.3M in Q4 2025. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.
- UBS Group held 561,165 shares of Crinetics Pharmaceuticals worth $21M as of Q2 2026.
- UBS Group sold 10,734 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $399K.
- Crinetics Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2629 holding.
- UBS Group first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 30 quarters since.
- UBS Group's Crinetics Pharmaceuticals position peaked at $42.3M in Q4 2025.
- 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.